DalsnaFinance Account

Intuitive Surgical $ISRG

Health Care · Health Care Equipment · NASDAQ

S&P 500 Nasdaq-100 Russell 1000 California

Create a scorecard

$427.86

+7.62 (+1.81%)

As of Oct 15, 2026, 10:26 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 18, 2026, the first target we tracked for ISRG.

Intuitive Surgical (ISRG) is trading up at $427.86 (+1.81%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on ISRG

Current price targets from 5 firms average $507, median $500, ranging from $400 to $685 — the average is 18% above the current $428. Each is tracked to its date and scored the same way a member's call is.

Oppenheimer $401 → $500 by Aug 2027 Outperform Aug 12, 2026 via Seeking Alpha · Oppenheimer's track record
Mizuho $345 → $400 by Jul 2027 Neutral Jul 18, 2026 via Stocktwits · Mizuho's track record
Citi $345 → $500 by Jul 2027 Buy Jul 18, 2026 via Stocktwits · Citi's track record
JPMorgan $345 → $450 by Jul 2027 Overweight Jul 18, 2026 via Stocktwits · JPMorgan's track record
Bernstein $345 → $685 by Jul 2027 Outperform Jul 18, 2026 via Stocktwits · Bernstein's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Intuitive Surgical revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Intuitive Surgical annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$2.71B	$3.14B	$3.72B	$4.48B	$4.36B	$5.71B	$6.22B	$7.12B	$8.35B	$10.1B
Growth (year over year)	+13.5%	+16.0%	+18.7%	+20.3%	−2.7%	+31.0%	+9.0%	+14.5%	+17.2%	+20.5%
Gross profit	$1.89B	$2.20B	$2.60B	$3.11B	$2.86B	$3.96B	$4.20B	$4.73B	$5.63B	$6.64B
Gross margin	69.9%	70.2%	69.9%	69.4%	65.6%	69.3%	67.4%	66.4%	67.5%	66.0%
Operating income	$949.7M	$1.06B	$1.20B	$1.37B	$1.05B	$1.82B	$1.58B	$1.77B	$2.35B	$2.95B
Operating margin	35.1%	33.9%	32.2%	30.7%	24.1%	31.9%	25.3%	24.8%	28.1%	29.3%
Net income	$738.3M	$670.9M	$1.13B	$1.38B	$1.06B	$1.70B	$1.32B	$1.80B	$2.32B	$2.86B
Net margin	27.3%	21.4%	30.3%	30.8%	24.3%	29.9%	21.3%	25.2%	27.8%	28.4%
EPS (diluted)	$2.09	$1.92	$3.16	$1.28	$2.94	$4.66	$3.65	$5.03	$6.42	$7.87
Balance sheet
Cash and equivalents	$1.04B	$648.2M	$857.9M	$1.17B	$1.62B	$1.29B	$1.58B	$2.75B	$2.03B	$3.37B
Total assets	$6.49B	$5.78B	$7.85B	$9.73B	$11.2B	$13.6B	$13.0B	$15.4B	$18.7B	$20.5B
Total liabilities	$709.1M	$996.4M	$1.16B	$1.45B	$1.41B	$1.60B	$1.86B	$2.04B	$2.21B	$2.52B
Shareholders' equity	$5.78B	$4.78B	$6.68B	$8.26B	$9.73B	$11.9B	$11.0B	$13.3B	$16.4B	$17.8B
Cash flow
Operating cash flow	$1.09B	$1.14B	$1.17B	$1.60B	$1.48B	$2.09B	$1.49B	$1.81B	$2.42B	$3.03B
Capital expenditure	$53.9M	$190.7M	$187.4M	$425.6M	$341.5M	$339.5M	$532.4M	$1.06B	$1.11B	$539.8M
Free cash flow	$1.03B	$953.2M	$982.2M	$1.17B	$1.14B	$1.75B	$958.4M	$749.6M	$1.30B	$2.49B
Share buybacks	$42.5M	$2.27B	$0	$269.5M	$134.3M	$0	$2.61B	$416.3M	$0	$2.30B

RevenueNet incomeNet margin (right axis, %)

Intuitive Surgical quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$2.04B	$2.41B	$2.25B	$2.44B	$2.51B	$2.87B	$2.77B	$2.89B
Growth (year over year)	+16.9%	+25.2%	+19.2%	+21.4%	+22.9%	+18.8%	+23.0%	+18.5%
Gross profit	$1.37B	$1.64B	$1.46B	$1.62B	$1.66B	$1.90B	$1.83B	$1.96B
Gross margin	67.4%	68.0%	64.7%	66.3%	66.4%	66.4%	66.1%	67.8%
Operating income	$577.3M	$734.9M	$578.1M	$743.4M	$759.7M	$864.3M	$855.3M	$971.9M
Operating margin	28.3%	30.4%	25.7%	30.5%	30.3%	30.2%	30.9%	33.6%
Net income	$565.1M	$685.7M	$698.4M	$658.4M	$704.4M	$794.8M	$821.5M	$818.1M
Net margin	27.7%	28.4%	31.0%	27.0%	28.1%	27.7%	29.6%	28.3%
EPS (diluted)	$1.56	$1.89	$1.92	$1.81	$1.95	$2.19	$2.28	$2.29
Balance sheet
Cash and equivalents	$2.41B	$2.03B	$2.57B	$3.40B	$2.81B	$3.37B	$2.01B	$2.76B
Total assets	$17.7B	$18.7B	$19.2B	$20.2B	$19.4B	$20.5B	$20.1B	$20.9B
Total liabilities	$2.07B	$2.21B	$2.01B	$2.21B	$2.31B	$2.52B	$2.51B	$2.58B
Shareholders' equity	$15.6B	$16.4B	$17.1B	$17.8B	$16.9B	$17.8B	$17.5B	$18.2B
Cash flow
Operating cash flow	$706.5M	$822.6M	$581.6M	$715.4M	$841.0M	$892.5M	$911.9M	$1.06B
Capital expenditure	$247.9M	$312.0M	$116.6M	$155.3M	$105.4M	$162.5M	$103.3M	$112.6M
Free cash flow	$458.6M	$510.6M	$465.0M	$560.1M	$735.6M	$730.0M	$808.6M	$948.4M
Dividends paid	$0	—	—	—	$0	—	—	—
Share buybacks	$0	$0	$0	$181.0M	$1.91B	$201.0M	$1.12B	$320.3M

From Intuitive Surgical's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Intuitive Surgical

Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world.

Source: Wikipedia — Intuitive Surgical